The efficacy of camptothecin-based topoisomerase I (Topo1) inhibitors, which are widely used as anticancer therapies, is often limited by resistance mechanisms, primarily involving mutations in the Topo1 enzyme and increased drug efflux mediated by ATP-binding cassette (ABC) transporters, particularly ABCG2 (BCRP).